DCR LLY12
Alternative Names: DCR-LLY12Latest Information Update: 28 Jan 2022
At a glance
- Originator Dicerna Pharmaceuticals
- Developer Dicerna Pharmaceuticals; Eli Lilly and Company
- Class Analgesics; Neuroprotectants; Small interfering RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Neurodegenerative disorders; Pain
Most Recent Events
- 28 Jan 2022 Dicerna Pharmaceutical enters in license with Elily Lilly for the development of DCR LLY12 for neurogenerative diseases and pain (Dicerna Pharmaceutical pipeline, January 2022)
- 20 Jan 2022 Dicerna Pharmaceuticals was acquired by Novo Nordisk
- 20 Jan 2022 Preclinical trials in Neurodegenerative disorders in USA (Parenteral) (Dicerna Pharmaceuticals pipeline, January 2022)